ZYBERNO
Stock Report
Updated Sep 1, 2026

Corvus Pharmaceuticals, Inc. (CRVS)

Healthcare • NASDAQ

$14.16

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Corvus Pharmaceuticals, Inc. (CRVS) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-36.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-393.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Corvus Pharmaceuticals, Inc. (CRVS) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CRVS generated -$34.99M in Owner Earnings. Capital was deployed as follows: $229.00K invested in capital expenditures. Reinvestment rate: -0.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:14.16
Market Cap:$1.31B

Valuation Multiples (2)

P/B Ratio:5.80x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.09B

Price Action & Momentum (1)

% of 52-Week High:52.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-33.6%
Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):0.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$4.52
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-33.3%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:16.16x
Quick Ratio:16.16x
Cash Ratio:15.74x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:207,293,000.00
Cash And Cash Equivalents:215,200,000.00
Long Term Debt:$274.00K
Net Debt:-$214.47M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$56.96M

Bottom Line Performance (3)

-$54.13M
Income Before Tax:-$51.79M
Ebitda Ttm:-56,846,000.00

Operating Expenses (5)

Operating Expenses:56,963,000.00
R And D Expense:45,532,000.00
Sga Expense:11,431,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$239.27M
Current Assets:$220.97M
Ppe Net:3,541,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:13,946,000.00
Current Liabilities:13,672,000.00
Long Term Debt:$274.00K
Short Term Debt:$454.00K

Equity & Capital (3)

Equity:$225.33M
Retained Earnings:-$443.94M
Common Stock:290,000,000.00

Working Capital Items (3)

Accounts Receivable:6,000.00
Inventory:0.00
Accounts Payable:4,047,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,609,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$34.91M-$35.14M

Investment Activities (2)

Investing Cash Flow:-$144.85M
Capital Expenditures Ttm:229,000.00

Financing Activities (3)

Financing Cash Flow:$190.75M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:189,407,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:117,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.64
-$0.64
Earnings Per Share Ttm:-$0.59

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.36

Book Value & Capital (2)

Book Value Per Share:$2.44
Cash Per Share:2.33

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$34.99M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):0.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):15.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:CRVS
Company Name:Corvus Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:92.37M
Shares Outstanding Basic:92.37M
Shares Outstanding Diluted:92.37M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 05:38:01 UTC
Data Timestamp:2026-09-01T05:38:01.731294
Scroll to Top